Efficacy and Safety of Ustekinumab and Vedolizumab for Crohn’s Disease of the Pouch
In one of the largest cohorts evaluating UST and VDZ for CD of the pouch thus far, these biologics were found to be safe and effective treatments for CD of the pouch.
Authors
- Mark Lazarev (ORCID: https://orcid.org/0000-0002-5517-3588)
- Laura Maas (ORCID: https://orcid.org/0000-0002-2401-2685)
- Kian Keyashian (ORCID: https://orcid.org/0000-0002-5333-2514)
- Andrew Ho (ORCID: https://orcid.org/0000-0003-1287-9844)
- Joseph Ebriani
- Alyssa Parian (ORCID: https://orcid.org/0000-0001-9995-7942)
- Berkeley N. Limketkai (ORCID: https://orcid.org/0000-0003-2714-6934)
- David Limsui
- Raúl Márquez Vázquez
- Jenny Sauk (ORCID: https://orcid.org/0000-0001-6731-8193)
- Sunhee Park
- Eleanor Yang (ORCID: https://orcid.org/0009-0001-1231-2859)
- Spencer Frost
- Nimisha Parekh
Institutions
- Johns Hopkins University (US)
- University of California, Los Angeles (US)
- Palo Alto University (US)
- University of California, Irvine (US)
- Johns Hopkins Medicine (US)
- Santa Clara Valley Medical Center (US)
- University of California, Irvine Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1093/ibd/izaf146
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00